371 related articles for article (PubMed ID: 30043449)
1. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children.
Masuyama K; Okamoto Y; Okamiya K; Azuma R; Fujinami T; Riis B; Ohashi-Doi K; Natsui K; Imai T; Okubo K
Allergy; 2018 Dec; 73(12):2352-2363. PubMed ID: 30043449
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
3. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
[TBL] [Abstract][Full Text] [Related]
4. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
[TBL] [Abstract][Full Text] [Related]
5. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
6. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
8. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.
Bernstein DI; Kleine-Tebbe J; Nelson HS; Bardelas JA; Sussman GL; Lu S; Rehm D; Svanholm Fogh B; Nolte H
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):105-110. PubMed ID: 29656145
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
10. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents.
Matsuoka T; Bernstein DI; Masuyama K; Nolte H; Okamiya K; Seitzberg D; Nelson HS
Pediatr Allergy Immunol; 2017 Nov; 28(7):661-667. PubMed ID: 28660739
[TBL] [Abstract][Full Text] [Related]
11. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study.
Okamiya K; Sekino H; Azuma R; Kudo M; Sakaguchi M; Nemoto F; Muramatsu N; Maekawa Y; Tanaka A
J Asthma; 2019 Dec; 56(12):1347-1355. PubMed ID: 30444150
[No Abstract] [Full Text] [Related]
13. Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population.
Okamoto Y; Fujieda S; Okano M; Hida H; Kakudo S; Masuyama K
Pediatr Allergy Immunol; 2019 Feb; 30(1):66-73. PubMed ID: 30281866
[TBL] [Abstract][Full Text] [Related]
14. House dust mite sublingual immunotherapy tablet safety in adolescents with allergic rhinoconjunctivitis: Worldwide clinical trial results.
Horn A; Bernstein DI; Okubo K; Dalgaard T; Hels O; Sørensen HF; Henriksen M; Azuma R; Mikler J; Nolte H
Ann Allergy Asthma Immunol; 2023 Jun; 130(6):797-804.e2. PubMed ID: 36924936
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study.
Li J; Wu Y; Yang Y; Huang N; Li W; Zhang S; Jiang Q; Yang L; Zhu R
Int Forum Allergy Rhinol; 2019 Aug; 9(8):876-882. PubMed ID: 31322838
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
Demoly P; Kleine-Tebbe J; Rehm D
Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
[TBL] [Abstract][Full Text] [Related]
17. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis.
Okamoto Y; Fujieda S; Okano M; Yoshida Y; Kakudo S; Masuyama K
Allergy; 2017 Mar; 72(3):435-443. PubMed ID: 27471838
[TBL] [Abstract][Full Text] [Related]
18. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
19. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial.
Wang DH; Chen L; Cheng L; Li KN; Yuan H; Lu JH; Li H
Laryngoscope; 2013 Jun; 123(6):1334-40. PubMed ID: 23616386
[TBL] [Abstract][Full Text] [Related]
20. Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.
Nelson HS; Bernstein DI; Biedermann T; Nolte H
Allergy Asthma Proc; 2024 Jan; 45(1):33-36. PubMed ID: 38151733
[No Abstract] [Full Text] [Related]
[Next] [New Search]
